(Total Views: 121)
Posted On: 05/05/2017 2:27:31 PM
Post# of 2218
$SGYP Synergy Pharmaceuticals (NASDAQ: SGYP) has been unfairly punished by the market in the first quarter of 2017. Its drug Trulance was approved for Chronic Idiopathic Constipation in December of last year. The company also just filed to have IBS-C added as an approved indication. Look for approval to happen sometime early in summer.
The drug is barely on the market and investors have taken the stock down from around $7.00 a share upon approval to just over $4.50 a share now. Trulance seems to be faster acting than market leading Linzess and has less side effects, especially diarrhea.
Linzess is growing nicely and is doing over $150 million a quarter in sales. Most recent analyst price targets on Synergy have been in the low teens. Investors need to let Trulance post a few quarters of sales and be patient on this one. Synergy is also a stock that is frequently mentioned as a buyout target.
The drug is barely on the market and investors have taken the stock down from around $7.00 a share upon approval to just over $4.50 a share now. Trulance seems to be faster acting than market leading Linzess and has less side effects, especially diarrhea.
Linzess is growing nicely and is doing over $150 million a quarter in sales. Most recent analyst price targets on Synergy have been in the low teens. Investors need to let Trulance post a few quarters of sales and be patient on this one. Synergy is also a stock that is frequently mentioned as a buyout target.
(0)
(0)
